Poseida Therapeutics (NASDAQ:PSTX) Given Buy Rating at HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reiterated by HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $20.00 price objective on the stock.

Poseida Therapeutics Stock Up 6.8 %

Poseida Therapeutics stock traded up $0.20 during trading hours on Friday, hitting $3.13. The company had a trading volume of 875,259 shares, compared to its average volume of 557,887. Poseida Therapeutics has a fifty-two week low of $1.87 and a fifty-two week high of $4.27. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.48 and a quick ratio of 2.48. The firm has a market capitalization of $304.02 million, a P/E ratio of -2.66 and a beta of 0.54. The firm’s fifty day moving average is $2.75 and its 200-day moving average is $2.87.

Poseida Therapeutics (NASDAQ:PSTX) last announced its quarterly earnings data on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. Poseida Therapeutics had a negative return on equity of 121.01% and a negative net margin of 127.48%. The business had revenue of $25.97 million during the quarter, compared to analyst estimates of $13.75 million. On average, research analysts forecast that Poseida Therapeutics will post -1.57 earnings per share for the current year.

Institutional Trading of Poseida Therapeutics

A number of institutional investors have recently added to or reduced their stakes in PSTX. The Manufacturers Life Insurance Company raised its holdings in shares of Poseida Therapeutics by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock valued at $83,000 after purchasing an additional 3,552 shares in the last quarter. Rhumbline Advisers boosted its holdings in Poseida Therapeutics by 4.2% during the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock valued at $283,000 after acquiring an additional 3,875 shares during the period. American Century Companies Inc. increased its position in Poseida Therapeutics by 5.9% in the 2nd quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock worth $264,000 after buying an additional 5,023 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Poseida Therapeutics by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock worth $1,749,000 after acquiring an additional 9,672 shares during the last quarter. Finally, Bayesian Capital Management LP bought a new position in Poseida Therapeutics during the first quarter worth $33,000. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.